Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies

被引:21
作者
Barbin, K
Stieglmaier, J
Saul, D
Stieglmaier, K
Stockmeyer, B
Pfeiffer, M
Lang, P
Fey, GH
机构
[1] Univ Erlangen Nurnberg, Dept Genet, Chair Genet, D-91058 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Dept Med 3, Div Hematol Oncol, D-91058 Erlangen, Germany
[3] Univ Tubingen, Univ Childrens Hosp, Dept Pediat Oncol, D-72076 Tubingen, Germany
关键词
N-glycosylation; antibody-dependent cellular cytotoxicity; therapeutic antibodies; leukemia; lymphoma;
D O I
10.1097/01.cji.0000175684.28615.7b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To investigate the influence of N-linked oligosaccharides at asparagines-297 on the cytolytic potential of chimeric CD19 antibodies, three distinct variants were generated by production in different expression systems. The same chimeric CD 19 antibody was produced in Sf21 insect cells, human 293 T cells, and 293T cells expressing a co-transfected beta 1,4-N-acetylglucosaminyltransferase III (GnTIII). The N-glycan structures and the cytolytic potential of the antibodies produced in these three systems were directly compared. After expression in insect cells, the antibody carried paucimannosidic N-linked oligosaccharides, distinct from the complex biantennary carbohydrate moieties attached to the product from human cells. After co-expression with GnTIII in human cells, the antibody carried an eightfold greater percentage of oligosaccharides with a bisecting N-acetylglucosamine (78.7% versus 9.6%) and a 30-fold increased proportion of bisecting, defucosylated oligosaccharides (15.9% versus 0.5%). The insect cell product triggered stronger anti body-dependent cellular cytotoxicity (ADCC) of a human leukemia-derived cell line than the product from non-re-engineered 293 T cells and was equally effective at 50- to 100-fold lower concentrations. The antibody from glyco-engineered 293 T cells had comparable lytic activity as the insect cell product. Both mediated significant ADCC at lower effector-to-target cell ratios than the antibody from non-re-engineered 293 T cells, and both were highly effective against primary blasts from pediatric leukemia patients. The data demonstrate the influence of the N-glycosylation pattern on the ADCC activity of chimeric CD19 antibodies and point to the importance of suitable expression systems for the production of highly active therapeutic antibodies.
引用
收藏
页码:122 / 133
页数:12
相关论文
共 50 条
[11]   INITIAL EXPERIENCE WITH TREATMENT OF HUMAN B-CELL LYMPHOMA WITH ANTI-CD19 MONOCLONAL-ANTIBODY [J].
HEKMAN, A ;
HONSELAAR, A ;
VUIST, WMJ ;
SEIN, JJ ;
RODENHUIS, S ;
HUININK, WWT ;
SOMERS, R ;
RUMKE, P ;
MELIEF, CJM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 32 (06) :364-372
[12]  
Hoelzer Dieter, 2002, Hematology Am Soc Hematol Educ Program, P162, DOI 10.1182/asheducation-2002.1.162
[13]   IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation [J].
Jefferis, R ;
Lund, J ;
Pound, JD .
IMMUNOLOGICAL REVIEWS, 1998, 163 :59-76
[14]   Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity [J].
Krapp, S ;
Mimura, Y ;
Jefferis, R ;
Huber, R ;
Sondermann, P .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 325 (05) :979-989
[15]   STRUCTURES OF THE N-LINKED OLIGOSACCHARIDES OF THE MEMBRANE-GLYCOPROTEINS FROM 3 LEPIDOPTERAN CELL-LINES (SF-21, IZD-MB-0503, BM-N) [J].
KUBELKA, V ;
ALTMANN, F ;
KORNFELD, G ;
MARZ, L .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 308 (01) :148-157
[16]   Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts [J].
Lang, P ;
Barbin, K ;
Feuchtinger, T ;
Greil, J ;
Peipp, M ;
Zunino, SJ ;
Pfeiffer, M ;
Handgretinger, R ;
Niethammer, D ;
Fey, GH .
BLOOD, 2004, 103 (10) :3982-3985
[17]   Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children [J].
Lang, P ;
Pfeiffer, M ;
Handgretinger, R ;
Schumm, M ;
Demirdelen, B ;
Stanojevic, S ;
Klingebiel, T ;
Köhl, U ;
Kuci, S ;
Niethammer, D .
BONE MARROW TRANSPLANTATION, 2002, 29 (06) :497-502
[18]  
Liang Mifang, 2001, P334
[19]   A UNIQUE HUMAN LYMPHOCYTE-B ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY [J].
MEEKER, TC ;
MILLER, RA ;
LINK, MP ;
BINDL, J ;
WARNKE, R ;
LEVY, R .
HYBRIDOMA, 1984, 3 (04) :305-320
[20]  
Messmann RA, 2000, CLIN CANCER RES, V6, P1302